32 results about "Prednisonum" patented technology

The invention discloses a 3-ketosteroid-delta1-dehydrogenase mutant and application thereof in synthesis of prednisone acetate, the mutant with high catalytic activity on cortisone acetate is obtained through screening, and a methanol-water phase (Tris-HCl buffer solution) system is adopted to increase the solubility of a substrate so as to improve the biological catalytic efficiency. In a single water phase system (Tris-HCl buffer solution) without methanol, the conversion efficiency is only 64.8% for 60g / L of cortisone acetate, and under the condition that other conditions are the same, the conversion rate in the Tris-HCl buffer solution system with methanol is increased to 92.1%, and the conversion rate is increased by 1.42 times.

The invention discloses a polymer material, a drug-loaded micelle solution, a drug-loaded micelle composite hydrogel, and a preparation method and application of the drug-loaded micelle composite hydrogel. The polymer material is obtained by reacting oxidized dextran and oleylamine; wherein the oxidized dextran is obtained by oxidizing dextran with the molecular weight of 35000 to 45000; the oxidation degree of the oxidized dextran is 55-70%; the mass ratio of the oxidized dextran to the oleylamine is 1: (1.2-2.0). The polymer material provided by the invention can form a micelle as a carrier to entrap a hydrophobic drug, such as prednisolone. The drug-loaded micelle composite hydrogel provided by the invention can be used for treating inflammatory bowel disease IBD, can avoid damage of an acid environment to a greater extent, and prolongs the administration time.

The invention belongs to the technical field of medicine detection, and particularly relates to an LCMS (Liquid Chromatography Mass Spectrometry) detection method for histamine in prednisolone. Respectively injecting the reference solution, the test solution and the blank solution into an LCMS (Liquid Chromatography Mass Spectrometer), recording a spectrogram, and calculating the content of histamine in prednisolone by adopting an external standard method; wherein the detection condition of the LCMS comprises a mobile phase, and the mobile phase adopts acetonitrile as a mobile phase A and a 10mM ammonium formate aqueous solution containing 0.1 vol% of formic acid as a mobile phase B. The method is good in reproducibility and stability and high in precision.

Provided are methods and compositions, for treating prostate cancer by administering to a patient in need thereof a therapeutically effective amount of a PARP inhibitor, e.g., niraparib; a therapeutically effective amount of a CYP17 inhibitor, e.g., abiraterone acetate, and a therapeutically effective amount of a glucocorticoid, e.g., prednisone.

The present disclosure relates to the use of cortisol, cortisone, cortisone acetate, hydrocortisone, fludrocortisone, prednisolone, prednisone, methylprednisolone, Dehydroepiandrosterone (DHEA), dexamethasone, betamethasone, adrenocorticotropic hormone (ACTH), ganaxolone, tetracosactide or combinations thereof for preventing and / or reducing the risk of Sudden Unexpected Death in Epilepsy (SUDEP). The disclosure further provides pharmaceutical compositions and methods for preventing and / or reducing the risk of SUDEP, particularly in Dravet Syndrome patients.

The present disclosure relates to niraparib and abiraterone acetate, plus prednisone or prednisolone; for use in a method of improving the efficacy of treatment of metastatic castration-resistant prostate cancer (mCRPC) in a patient with DNA-repair anomalies, in particular for improving the median radiographic progression-free survival (rPFS).

The application provides a culture method and composition for prolonging the in-vitro survival time of neutrophils. The composition provided by the application comprises prednisolone and beta-mercaptoethanol, which can prolong the survival time of neutrophils. The method provided by the application has low cost, simple operation, small interference to cell function, can guarantee an experimental window of 3-4 days, and has good application value.

The invention discloses a compound with an anti-osteoporosis effect and a preparation method of the compound with the anti-osteoporosis effect. The preparation method comprises the following steps: separating from a fermentation solution of a fungus Talaromyces pinophilus (CICC 2707), so as to obtain new compounds, i.e., acetosellin B and acetosellin C. The invention further discloses a preparation method of the compound with the anti-osteoporosis effect and a preparation method of the compound with the anti-osteoporosis effect. Experiments show that prednisolone-induced zebra fish osteoporosis models are selected to carry out experiments on the prepared compounds acetosellin B and acetosellin C, and the compounds are found to have relatively high in-vivo osteogenic activity of zebra fish and can be used for preparing medicines for preventing and treating osteoporosis.

This invention provides a strain of *Lactobacillus plantarum*, and discloses the fermentation product of *Eucommia ulmoides* leaves, *Rehmannia glutinosa*, dried ginger, and *Dendrobium officinale* obtained by fermenting these herbs, along with its preparation method and applications. This fermentation product can directionally activate the phenylpropane biosynthetic pathway, inducing the generation of characteristic small molecule metabolites of polyphenols, particularly sanguranyl sulfadiazine (SSA). Moreover, compared to the raw materials, the fermentation product contains more active small molecule metabolites. Finally, experiments on zebrafish modeled with prednisone demonstrated that the fermentation product can significantly promote bone formation. The fermentation product mainly restores the expression levels of related genes to normal zebrafish gene expression levels by regulating these genes. Therefore, the fermentation product can be used to prepare foods or medicines that improve bone health.

The application provides a traditional Chinese medicine composition for treating chronic primary thrombocytopenia, a preparation and application thereof, and relates to the technical field of traditional Chinese medicine compositions. The traditional Chinese medicine composition comprises the following traditional Chinese medicine raw materials in parts by weight: 10-50 parts of Semen Euryae, 10-50 parts of Herba Epimedii, 10-50 parts of Radix Paeoniae Alba, 10-40 parts of Radix Rehmanniae, 10-40 parts of Folium Forsythiae and 3-20 parts of Cinnamomum Cassia. Pharmacological and pharmacodynamic experimental results prove that the traditional Chinese medicine composition can obviously reduce the bleeding grade of model mice, increase the platelets of model mice, has an effect equivalent to that of prednisone acetate, and is superior to that of Jinshuye mixture. The composition can effectively treat chronic primary thrombocytopenia by regulating the kidney and the spleen, and removing the root pathogenesis of deficiency of kidney yang caused by toxic evil lingering.

The invention provides application of a composition in preparation of a medicine for treating chronic nephritis, and relates to the field of traditional Chinese medicine preparations. The composition is prepared from the following components in parts by weight: 1 to 4 parts of radix rehmanniae total iridoid glycoside extract, 2 to 6 parts of fructus corni total iridoid glycoside extract and 0.5 to 1.5 parts of fructus corni total triterpene acid extract. The composition shows remarkable drug effects in the aspects of improving the survival state of rats with chronic nephritis, reducing 24-hour urine protein, reducing kidney indexes, reducing hematuria, inhibiting inflammation and the like, and has excellent multiple treatment effects, particularly, the effect of the composition in a specific combination proportion range is equivalent to that of a positive control drug prednisone acetate group, and the composition has good clinical application prospects. And the performance is even better in some indexes.

The present disclosure provides ophthalmic compositions comprising a steroid, such as prednisolone encapsulated in a liposomal carrier and methods of use thereof.

The invention provides a method for detecting the content of aflatoxin B1, B2, G1 and G2 in prednisolone through a fermentation process, which comprises the following steps: A) dissolving a sample to be detected by adopting a solvent, performing ultrasonic extraction, and filtering to obtain a liquid to be detected; b) preparing a mixed standard control solution of aflatoxin B1, B2, G1 and G2; and C) carrying out qualitative and quantitative analysis on the to-be-detected solution and the mixed standard control solution by adopting HPLC-MS / MS to obtain a detection result. According to the method disclosed by the invention, a rapid and simple pretreatment mode is combined with high performance liquid chromatography-triple quadrupole mass spectrometry, so that the aflatoxin B1, B2, G1 and G2 detection sensitivity is high, the separation degree and peak shape are good, and the detection result is reliable.

The invention relates to the technical field of biology, in particular to a dissociation agent and a kit for progesterone determination. According to the invention, the sample dissociation agent for progesterone detection is obtained through optimized screening, and the sample dissociation agent comprises hydrocortisone, prednisolone and mono (2-ethylhexyl) phthalate (MEHP); when the dissociation agent components act independently or in a combined mode, the sensitivity to sample detection is high, the detection linear range is good, the dissociation agent is well related to a comparison reagent, the dissociation effect is improved remarkably on the whole, progesterone can be better released from corticosteroid binding protein, albumin and sex hormone binding globulin, and the progesterone dissociation agent is suitable for being used for detecting progesterone. The combination of progesterone and a captured antibody is facilitated, and the sensitivity and the accuracy can be effectively improved. Moreover, the reagent can be directly added into reagent components, so that the dissociation process and the immune reaction are carried out at the same time, the immune reaction is simple and efficient, and the reaction efficiency is improved.

The present invention discloses a method for preparing prednisolone by one-step fermentation, using Nocardia simplex as the fermentation strain, and performing C 1,2 -position dehydrogenation and C 21 -position hydrolysis in one step to convert compound I into compound IV. The optimized fermentation process of the present invention has a conversion rate of 95%-98%, few by-products, a product purity greater than 99.5%, and an overall yield of more than 80%. The present invention uses a powder-liquid mixer device that integrates microcrystallization and substrate sterilization, simplifies the pretreatment process of steroid substrates, improves production efficiency, enhances the substrate sterilization effect, does not use cosolvents, and reduces costs.

To provide a liquid or semi-solid composition comprising prednisolone valerate acetate in an amount of more than 0.15 mass% based on the total mass of the composition, which suppresses crystal precipitation when stored under low-temperature conditions.SOLUTION: A liquid or semi-solid composition comprises: (A) prednisolone valerate acetate in an amount of more than 0.15 mass% based on the total mass of the composition; and (B) a panthenol.SELECTED DRAWING: None

The invention provides an application of metformin in preparation of a medicine for preventing or treating immune checkpoint inhibitor related colitis. It is found through experiments that when the immune checkpoint inhibitor causes colitis, change of metabolic level represented by glycolysis caused by change of a PI3K / AKT / mTOR pathway in the colon is obviously accompanied, then Treg / Th17 steady state in the colon is affected, and a high inflammatory state is shown in the colon. According to the present invention, the influence on glycolysis and other metabolic pathways is achieved through the targeted interference of the metformin on the PI3K / AKT / mTOR pathway, the colitis caused by the immune checkpoint inhibitor can be significantly improved, the anti-tumor drug effect of the immune checkpoint inhibitor is not affected, and the method is generally superior to the original clinical methylprednisolone intervention scheme.

The invention relates to hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biological hydrogel materials. The hydrogel comprises a prednisolone sodium phosphate hydrogel P-Gel skeleton and gold nanoparticles PCAu, wherein the gold nanoparticles PCAu are uniformly loaded on the P-Gel skeleton and are coated by procyanidine. According to the preparation method, a three-dimensional cross-linked network skeleton of PSP hydrogel P-Gel is self-assembled and constructed by utilizing ion coordination and hydrogen-bond interaction of prednisolone sodium phosphate PSP under the action of Ca < 2 + >, and the hydrogel PCAu-coated P-Gel is formed by uniformly loading gold nanoparticles PCAu which are green synthesized from procyanidine PC and have stable surfaces. The hydrogel can promote rapid repair of spinal cord injury and relieve far-end muscle atrophy and fibrosis; and meanwhile, the injectable self-healing hydrogel has the engineering advantages of injectability, self-healing and the like, and shows good clinical transformation potential.

Methods and compositions are provided for treating prostate cancer by administering to a patient in need thereof a therapeutically effective amount of a PARP inhibitor, e.g., niraparib, a therapeutically effective amount of a CYP17 inhibitor, e.g., abiraterone acetate, and a therapeutically effective amount of a glucocorticoid, e.g., prednisone.

An object of the present invention is to provide a formulation technique for improving the solubility and safety of Prednisolone Valerate Acetate in an external pharmaceutical composition containing Prednisolone Valerate Acetate.SOLUTION: An external pharmaceutical composition comprising Prednisolone Valerate Acetate and propylene glycol monocaprylate.SELECTED DRAWING: None

The present disclosure provides ophthalmic compositions comprising a steroid, such as prednisolone encapsulated in a liposomal carrier and methods of use thereof.

The invention provides application of a KRAS inhibitor combined with glucocorticoid in preparation of a medicine for treating cancers, and belongs to the technical field of biological medicines. The invention provides a combined application of a KRAS inhibitor and glucocorticoid in preparation of a medicine for treating cancers. Compared with the single use of the KRAS inhibitor or prednisolone, the combined use of the KRAS inhibitor and prednisolone can more effectively inhibit the proliferation and survival of KRAS G12C mutated NSCLC cells and slow down the growth of tumor volume. In addition, prednisolone can relieve the acquired drug resistance problem of KRASi by blocking generation of TNF and I-type IFN induced by a KRAS inhibitor, and prednisolone and prednisolone have a synergistic anti-tumor effect. The two can be directly combined for medication, can also be prepared into a combined agent for treating cancers, and has a good clinical transformation prospect.

The invention provides an application of glutamine in treatment of primary nephrotic syndrome and an application thereof, and particularly relates to an application of a combination of glutamine or a derivative thereof or glutamine guat acid sodium and prednisone acetate in preparation of a medicine, and the medicine is used for preventing, relieving and / or treating the primary nephrotic syndrome. According to the application disclosed by the invention, the glutamine or the derivative thereof and the prednisone acetate are combined for use, so that the negative conversion time of the primary nephrotic syndrome can be effectively shortened, the times of later recurrence and infection are reduced, the prognosis effect is improved, and a new thought is provided for preventing, relieving and / or treating the primary nephrotic syndrome.

The invention relates to a compound of formula:which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.

This invention discloses a quantitative analysis method for the blood concentrations of HYQ-169 and prednisolone and its application, belonging to the fields of medical testing and pharmaceutical analysis. The quantitative analysis method includes the following steps: preparing standard curve samples and quality control samples; adding internal standard solution; extracting with ethyl acetate; drying the supernatant and reconstituteing; separating using SPE; drying the fraction and reconstituteing again; detecting using UPLC-MS / MS; establishing a standard curve and obtaining a regression equation; adding internal standard solution to the plasma sample to be tested and processing it in the same way; calculating the blood concentrations of HYQ-169 and prednisolone according to the regression equation. This invention can simultaneously perform quantitative detection of two drug components with significantly different chemical properties in a single analysis, with high sensitivity, high accuracy, and fast analysis speed, providing a foundation for preclinical and clinical pharmacokinetic studies of HYQ-169.

Described herein are methods for reducing an antibody response to uricase therapy, improving the treatment of gout, reducing uric acid levels, and preventing and / or delaying infusion reactions. The methods may include administration of a uricase and a steroid as described herein.

The use of a mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone in the preparation of a drug for treating peripheral T-cell lymphoma (PTCL). The PTCL is preferably treatment-naïve PTCL. Other first-line and second-line drugs for treating PTCL may also be further used on the basis of the foregoing. A method for treating PTCL, the method comprising administering, to a patient, a therapeutically effective amount of a mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone. The combined administration of the drugs is safe and tolerable, has a small toxicity and few side effects, and can obtain a higher total objective remission rate (ORR) in treatment-naïve PTCL patients.

The invention relates to the field of pharmaceutical preparation analysis and detection, in particular to a method for detecting the content of prednisolone sodium succinate for injection. The invention relates to a method for detecting the content of prednisolone sodium succinate for injection, which adopts high performance liquid chromatography for detection, and the high performance liquid chromatography conditions comprise: a chromatographic column using octadecylsilane chemically bonded silica as a filler; the mobile phase is a mixture of a component A and a component B; the component A is a mixed solution of a monopotassium phosphate solution, acetonitrile and tetrahydrofuran; the concentration of the monopotassium phosphate solution is 0.01 mol / L to 0.03 mol / L; the component B is a mixed solution of acetonitrile and water; the invention discloses a method for detecting the content of prednisolone sodium succinate for injection, which is a detection method with good system applicability, specificity, linear relation, precision, repeatability, accuracy, stability and durability, and is used for effectively detecting the content of prednisolone in the prednisolone sodium succinate.

To provide a liquid or semi-solid composition comprising prednisolone valerate acetate in an amount of more than 0.15 w / v% based on the total volume of the composition, which suppresses crystal precipitation when stored under low-temperature conditions.SOLUTION: A liquid or semi-solid composition comprises: (A) prednisolone valerate acetate in an amount of more than 0.15 w / v% based on the total volume of the composition; and (B) a salicylic acid.SELECTED DRAWING: None

The invention discloses a medicine for treating rheumatic diseases and a preparation method thereof. The medicine is prepared from a traditional Chinese medicine composition and prednisone acetate, according to the traditional Chinese medicine composition, traditional Chinese medicine and western medicine are combined, the western medicine prednisone acetate is used for rapidly resisting inflammation, controlling main symptoms (red, swelling, heat, pain and stiff), relieving the pain of a patient and rapidly treating symptoms, and time is bought for long-acting conditioning of the traditional Chinese medicine composition; the traditional Chinese medicine composition is reasonably matched, so that lasting anti-inflammation, wind dispelling, dampness eliminating, blood circulation promoting, collateral dredging and internal environment improving are realized through multiple ways and multiple targets; the traditional Chinese medicine composition can tonify liver and kidney, regulate immune homeostasis, regulate whole body conditions, enhance body immunity, improve patient physique, treat both symptoms and root causes, and give consideration to both evil and positive qi.